|
|
|
| |
 |
|
| |
|
|
| |
We have developed a dry powder inhaler device that is far more efficient than comparable marketed devices used in the treatment of asthma and COPD. |
|
|
|
|
| |
Currently available inhaler devices that are designed to deliver medication directly to the lungs have serious design shortcomings - a minor fraction of the administered drug reaches the lungs, a major part of the dose deposits in the throat lining from which it is absorbed. |
|
|
|
|
|
Further, in most inhalers the patient needs to make an effort to inhale the medication, which could be difficult when the patient has asthma, or is very old or young. There is no counter to indicate whether a dose has been administered or not, which may result in repeat dosing. |
|
|
|
|
|
Our device addresses all these issues. It enables a major part of the drug inhaled to be delivered to the lungs - hence it may be possible to reduce the dose administered. |
|
|
|
|
|
Our device complies completely with the US and European guidelines for inhalers - several marketed inhalers do not comply completely. |
|
|
|
|
|
The device offers a audible and visual feedback of a dose that has been administered. This device delivers similar dose across the patient effort and hence the very old and young can use it with equal ease. The device can be used to deliver existing asthma medication, or new steroid molecules. |
|
|
|
|
|
|
|
